Physician profile
Melissa Mccarter
NPI 1356305106
$12,564.86
in general payments reported to CMS, 2019-2025
33 companies · $2,975 in 2025
The $2,975 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,202 · 2022: $2,113 · 2023: $2,963 · 2024: $2,313 · 2025: $2,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,249 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,249.02 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,756.18 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,074.49 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,030.33 | 2021-2025 | Caplyta |
| Lundbeck LLC | $966.05 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $956.09 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $843.83 | 2021-2025 | |
| Axsome Therapeutics, INC. | $806.18 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $794.07 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $761.37 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $558.32 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $486.86 | 2021-2025 | Spravato, Invega Sustenna |
| Bausch Health US, LLC | $384.42 | 2021-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $344.58 | 2022-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $282.66 | 2021 | |
| Supernus Pharmaceuticals, INC. | $243.35 | 2022-2025 | Qelbree, Qelbree |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $229.16 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $188.04 | 2025 | Cobenfy |
| Almatica Pharma LLC | $127.83 | 2022-2023 | Loreev Xr |
| Gilead Sciences, INC. | $101.06 | 2025 | Trodelvy |
| Seagen INC. | $99.99 | 2022 | |
| Eisai INC. | $88.45 | 2021 | |
| Neos Therapeutics, LP | $82.71 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Astrazeneca Pharmaceuticals LP | $80.29 | 2023-2025 | Imfinzi |
| Idorsia Pharmaceuticals US INC | $54.79 | 2022-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $40.85 | 2023 | Horizant |
| Acadia Pharmaceuticals INC | $37.08 | 2021 | |
| Adlon Therapeutics L.P. | $26.78 | 2021 | |
| Indivior INC. | $21.61 | 2022 | |
| Sobi, INC | $21.23 | 2024 | |
| Ironshore Pharmaceuticals INC. | $20.28 | 2022 | |
| Noven Therapeutics, LLC | $20.00 | 2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $18.63 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $17.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mccarter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.